Valuation: Orion Oyj

Market Cap 10.12B 11.54B 9.33B 8.64B 16.39B 1,097B 16.66B 112B 43.5B 541B 43.33B 42.38B 1,873B P/E 2026 *
18.4x
P/E 2027 * 15.6x
Enterprise Value 10.02B 11.43B 9.24B 8.56B 16.22B 1,086B 16.49B 111B 43.07B 535B 42.9B 41.96B 1,854B EV / Sales 2026 *
4.81x
EV / Sales 2027 * 4.17x
Free-Float
90.5%
Yield 2026 *
2.65%
Yield 2027 * 2.94%
1 day+2.29%
1 week-0.14%
Current month-0.14%
1 month+3.02%
3 months+0.56%
6 months+8.98%
Current year+13.11%
1 week 68.3
Extreme 68.3
72.6
1 month 66
Extreme 66
72.6
Current year 62.3
Extreme 62.3
75.1
1 year 56.3
Extreme 56.3
75.1
3 years 32.5
Extreme 32.5
75.1
5 years 32.5
Extreme 32.5
75.1
10 years 24.75
Extreme 24.75
75.1
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.29%-0.14% - - 11.32B
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-0.04%+1.20%+35.72%+87.93% 450B
-2.58%-2.07%+27.62%+22.57% 328B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
+1.48%-0.04%-4.64%-32.25% 135B
Average +1.01%+2.20%+26.94%+53.47% 385.27B
Weighted average by Cap. +0.30%+2.51%+41.85%+87.34%

Financials

2026 *2027 *
Net sales 2.08B 2.37B 1.92B 1.78B 3.37B 226B 3.43B 23.01B 8.95B 111B 8.91B 8.72B 385B 2.35B 2.68B 2.17B 2.01B 3.81B 255B 3.87B 26.03B 10.12B 126B 10.08B 9.86B 436B
Net income 550M 627M 507M 469M 890M 59.57B 905M 6.08B 2.36B 29.36B 2.35B 2.3B 102B 649M 740M 599M 554M 1.05B 70.38B 1.07B 7.18B 2.79B 34.68B 2.78B 2.72B 120B
Net Debt -100M -114M -92.58M -85.75M -163M -10.88B -165M -1.11B -432M -5.36B -430M -421M -18.58B -312M -355M -287M -266M -504M -33.77B -513M -3.44B -1.34B -16.64B -1.33B -1.3B -57.67B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
07/07/26 EUR 71.60 +2.29% 1,952
06/07/26 EUR 70.00 -2.37% 6,842
03/07/26 EUR 71.70 -0.55% 956
02/07/26 EUR 72.10 +2.27% 7,592
01/07/26 EUR 70.50 -1.67% 2,841
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
71.90EUR
Average target price
74.33EUR
Spread / Average Target
+3.38%

Quarterly revenue - Rate of surprise